- Home
- CTOS vs JANX Comparison
CTOS vs JANX Comparison
Compare CTOS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOS
- JANX
- Stock Information
- Founded
- CTOS 1988
- JANX 2017
- Country
- CTOS United States
- JANX United States
- Employees
- CTOS N/A
- JANX N/A
- Industry
- CTOS Diversified Commercial Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- CTOS Consumer Discretionary
- JANX Health Care
- Exchange
- CTOS Nasdaq
- JANX Nasdaq
- Market Cap
- CTOS 1.4B
- JANX 1.4B
- IPO Year
- CTOS N/A
- JANX 2021
- Fundamental
- Price
- CTOS $6.21
- JANX $22.42
- Analyst Decision
- CTOS Buy
- JANX Strong Buy
- Analyst Count
- CTOS 3
- JANX 11
- Target Price
- CTOS $6.83
- JANX $76.55
- AVG Volume (30 Days)
- CTOS 809.8K
- JANX 761.7K
- Earning Date
- CTOS 10-29-2025
- JANX 11-05-2025
- Dividend Yield
- CTOS N/A
- JANX N/A
- EPS Growth
- CTOS N/A
- JANX N/A
- EPS
- CTOS N/A
- JANX N/A
- Revenue
- CTOS $1,901,675,000.00
- JANX $439,000.00
- Revenue This Year
- CTOS $13.58
- JANX N/A
- Revenue Next Year
- CTOS $5.18
- JANX $130.50
- P/E Ratio
- CTOS N/A
- JANX N/A
- Revenue Growth
- CTOS 6.21
- JANX N/A
- 52 Week Low
- CTOS $3.03
- JANX $21.73
- 52 Week High
- CTOS $6.64
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- CTOS 53.56
- JANX 43.25
- Support Level
- CTOS $6.28
- JANX $23.00
- Resistance Level
- CTOS $6.59
- JANX $24.57
- Average True Range (ATR)
- CTOS 0.24
- JANX 1.22
- MACD
- CTOS 0.03
- JANX -0.02
- Stochastic Oscillator
- CTOS 61.98
- JANX 19.78
About CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.